Building Non-Interventional Studies for Regulatory Purposes

As regulators place increasing weight on real-world evidence, non-interventional study designs are taking on a larger role across the pharma life cycle. The problem: too many are designed backwards, built from the data that happens to be available rather than from the regulatory question they need to answer. Join OM1 Founder Dr. Rich Gliklich and Senior Director of Registries Michelle Leavy for a webinar that makes the case for a build-for-purpose mindset, in which every design decision flows from a clearly defined regulatory objective. | Registries, Observational Studies, and External Control Arms

Raccontata dafiercepharma.com